Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription


2 Ann Surg Oncol
3 Ann Thorac Surg
4 Anticancer Res
3 BMC Cancer
2 Cancer
2 Cancer Lett
1 Chest
3 Clin Lung Cancer
2 Eur J Cancer
2 Eur J Cardiothorac Surg
1 Eur Respir J
1 Int J Oncol
1 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
3 Lancet Oncol
5 Lung Cancer
1 N Engl J Med
1 Oncogene
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

    Commentary: The Role of PET Scan Uptake in Determining Prognosis in Early-Stage Lung Cancer.
    Ann Surg Oncol. 2022 Nov 28. doi: 10.1245/s10434-022-12687.

  2. UIMONEN M, Helminen O, Bohm J, Mrena J, et al
    Standard Lymphadenectomy for Esophageal and Lung Cancer: Variability in the Number of Examined Lymph Nodes Among Pathologists and Its Survival Implication.
    Ann Surg Oncol. 2022 Nov 25. doi: 10.1245/s10434-022-12826.
    PubMed         Abstract available

    Ann Thorac Surg

  3. ANDREWS WG, Louie BE, Bograd AJ
    Resection of Persistent Stage IIIA-N2 Non-small Cell Lung Cancer After Induction Therapy.
    Ann Thorac Surg. 2022;114:2392-2393.

  4. ALOZIE A, Werner D, Schafmayer C, Yilmaz K, et al
    Management of Pulmonary Artery Synovial Sarcoma: The 3-Step Surgical Approach.
    Ann Thorac Surg. 2022;114:e443-e445.
    PubMed         Abstract available

  5. KENNEDY GT, Azari FS, Bernstein E, Desphande C, et al
    3D Specimen Mapping Expedites Frozen Section Diagnosis of Nonpalpable Ground Glass Opacities.
    Ann Thorac Surg. 2022;114:2115-2123.
    PubMed         Abstract available

    Anticancer Res

  6. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Detailed Surgical Techniques and Short-term Clinical Outcomes of Sleeve Lobectomy for Locally Advanced Right Lower Lobe Lung Cancer.
    Anticancer Res. 2022;42:5977-5982.
    PubMed         Abstract available

  7. LIM CH, Koh YW, Hyun SH, Lee SJ, et al
    A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:5875-5884.
    PubMed         Abstract available

  8. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Overall Survival of Small-cell Lung Cancer Patients With Malignant Central Airway Obstruction Who Received Chemotherapy Without Undergoing Transbronchial Interventions: A Single-institution Retrospective Study.
    Anticancer Res. 2022;42:6113-6119.
    PubMed         Abstract available

  9. PARTYNSKA A, Piotrowska A, Pawelczyk K, Rzechonek A, et al
    The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:5731-5741.
    PubMed         Abstract available

    BMC Cancer

  10. SUN B, Hou Q, Liang Y, Xue S, et al
    Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer.
    BMC Cancer. 2022;22:1233.
    PubMed         Abstract available

  11. CACCIALANZA R, Cereda E, Agustoni F, Klersy C, et al
    Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.
    BMC Cancer. 2022;22:1212.
    PubMed         Abstract available

  12. LIANG ZR, Ye M, Lv FJ, Fu BJ, et al
    Differential diagnosis of benign and malignant patchy ground-glass opacity by thin-section computed tomography.
    BMC Cancer. 2022;22:1206.
    PubMed         Abstract available


  13. CRONIN KA, Scott S, Firth AU, Sung H, et al
    Annual report to the nation on the status of cancer, part 1: National cancer statistics.
    Cancer. 2022;128:4251-4284.
    PubMed         Abstract available

  14. LEE Y, Kim HR, Hong MH, Lee KH, et al
    A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
    Cancer. 2022 Nov 30. doi: 10.1002/cncr.34553.
    PubMed         Abstract available

    Cancer Lett

  15. TIAN Y, Xu L, Li X, Li H, et al
    SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
    Cancer Lett. 2022 Nov 27:216022. doi: 10.1016/j.canlet.2022.216022.
    PubMed         Abstract available

  16. TANG B, Wang Y, Xu W, Zhu J, et al
    Macrophage-specific xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer.
    Cancer Lett. 2022 Nov 28:216021. doi: 10.1016/j.canlet.2022.216021.
    PubMed         Abstract available


  17. RICHMOND J, Murray MH, Milder CM, Blume JD, et al
    Racial Disparities in Lung Cancer Stage of Diagnosis among Adults Living in the Southeastern U.S.
    Chest. 2022 Nov 23:S0012-3692(22)04195-2. doi: 10.1016/j.chest.2022.
    PubMed         Abstract available

    Clin Lung Cancer

  18. LIU B, Wang Z, Zhao H, Gao S, et al
    The Value of Radiotherapy in Patients With Resectable Stage IIIA Non-Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis.
    Clin Lung Cancer. 2022 Oct 13:S1525-7304(22)00212.
    PubMed         Abstract available

  19. TRAN JH, Mhango G, Park HS, Marshall DC, et al
    Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm.
    Clin Lung Cancer. 2022 Nov 1:S1525-7304(22)00242.
    PubMed         Abstract available

  20. GAZEU A, Aubert M, Pissaloux D, Lantuejoul S, et al
    Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
    Clin Lung Cancer. 2022 Nov 1:S1525-7304(22)00241.
    PubMed         Abstract available

    Eur J Cancer

  21. SAW SPL, Ng WP, Zhou S, Lai GGY, et al
    PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
    Eur J Cancer. 2022;178:139-149.
    PubMed         Abstract available

  22. SHE Y, Li S, Deng J, Ren Y, et al
    Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
    Eur J Cancer. 2022;177:53-62.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  23. KITAZUME M, Tane S, Shimizu N, Kitamura Y, et al
    Segmental volumetric analysis with a ventilated or perfused area: identifying the intersegmental plane.
    Eur J Cardiothorac Surg. 2022;62:ezac537.
    PubMed         Abstract available

  24. NAKADA T, Takahashi Y, Sakakura N, Masago K, et al
    Postoperative surveillance using low-dose computed tomography for non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2022 Nov 28:ezac549. doi: 10.1093.
    PubMed         Abstract available

    Eur Respir J

  25. EYMIN B
    Inspiratory hyperoxia: a new way to prevent metastasis through metabolism reprogramming in non-small cell lung cancer.
    Eur Respir J. 2022;60:2201357.

    Int J Oncol

  26. YANG Y, Zheng X, Ni P, Li D, et al
    Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC.
    Int J Oncol. 2023;62:12.
    PubMed         Abstract available

    J Natl Cancer Inst

  27. HEIDEN BT, Eaton DB, Chang SH, Yan Y, et al
    Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac208. doi: 10.1093.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  28. KALATA S, Lam GT, Alnajjar RM, Clark MJ, et al
    Adequate lung cancer surgery lymphadenectomy within a statewide quality collaborative: Quality improvement in action.
    J Thorac Cardiovasc Surg. 2022 Oct 28:S0022-5223(22)01150.
    PubMed         Abstract available

    Lancet Oncol

    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e529.

  30. GANGULY S, Gogia A
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e528.

  31. UPRETY D
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e527.

    Lung Cancer

  32. PARK BJ, Woo W, Cha YJ, Shim HS, et al
    Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion.
    Lung Cancer. 2022;175:1-8.
    PubMed         Abstract available

  33. JIANG J, Tang C, Li Y, Lin Z, et al
    Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test.
    Lung Cancer. 2022;175:9-16.
    PubMed         Abstract available

  34. BODD MH, Locke SC, Wolf SP, Antonia S, et al
    Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
    Lung Cancer. 2022;175:17-26.
    PubMed         Abstract available

  35. SUBRAMANIAN J, Leighl NB, Choi YL, Chou TY, et al
    Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
    Lung Cancer. 2022;175:47-56.
    PubMed         Abstract available

  36. LORENZ J, Moghanaki D, Keshava H, Harpole DH, et al
    Sins of omission: A meta-research study evaluating the omission of operability in published retrospective comparisons of surgery with stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer.
    Lung Cancer. 2022;175:57-59.
    PubMed         Abstract available

    N Engl J Med

  37. TEMEL JS, Dudzinski DM, Digumarthy SR, Keyes CM, et al
    Case 35-2022: A 60-Year-Old Man with Progressive Dyspnea, Neck Swelling, and a Lung Mass.
    N Engl J Med. 2022;387:1889-1896.


  38. THIRUSANGU P, Ray U, Sarkar Bhattacharya S, Oien DB, et al
    Correction to: PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
    Oncogene. 2022 Nov 28. doi: 10.1038/s41388-022-02470.

    PLoS One

  39. DENG J, Huang Y, Wu X, Hong Y, et al
    Comparison of dosimetric effects of MLC positional errors on VMAT and IMRT plans for SBRT radiotherapy in non-small cell lung cancer.
    PLoS One. 2022;17:e0278422.
    PubMed         Abstract available

  40. RAI SN, Das S, Pan J, Mishra DC, et al
    Multigroup prediction in lung cancer patients and comparative controls using signature of volatile organic compounds in breath samples.
    PLoS One. 2022;17:e0277431.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.